A phase-II trial compared neoadjuvant ipilimumab (anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4), IPI) plus nivolumab (anti-programmed cell death protein-1 (PD-1), NIVO) to neoadjuvant NIVO alone, in patients with stages I-IIIA NSCLC, and reported pathological complete response rates (pCR) of 29% with IPI-NIVO and 9% with NIVO alone in the intention-to-treat (ITT) population, and in the resected patient population: 38% with IPI-NIVO and 10% with NIVO alone.11 The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.